Lazarus M N, Robinson D, Mak V, Møller H, Isenberg D A
Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK.
Rheumatology (Oxford). 2006 Aug;45(8):1012-5. doi: 10.1093/rheumatology/kei281. Epub 2006 Feb 20.
To compare the incidence of subsequent cancers in a cohort of patients with primary Sjögren's syndrome (pSS) with that of the general population in the same region of England.
A retrospective analysis was carried out on 112 patients who had attended the out-patients department at University College Hospital, London, from 1979 onwards. Patients were followed up from diagnosis of pSS to diagnosis of first subsequent cancer, death, loss to follow-up or 31 December 2003 (the censoring date) to determine the person-years at risk for each individual. The expected numbers of subsequent cancers were calculated from sex-/age-/period-specific rates for the general population of southeast England, derived from registrations at the Thames Cancer Registry. Standardized incidence ratios (SIRs) were then calculated as the ratio of observed to expected numbers of cancers, along with 95% confidence intervals (CIs). Separate analyses were performed for all malignant cancers combined, lymphomas and non-lymphoid cancers.
Among the 112 patients with pSS, 25 developed cancer (either before or after development of pSS), with lymphoma occurring in 11 cases. Nine patients had two cancers. There was a significantly elevated incidence of lymphomas in pSS patients compared with the general population (SIR 37.5, 95% CI 20.7-67.6). For non-lymphoid cancer, the observed increase in incidence was small and not statistically significant (SIR 1.5, 95% CI 0.9-2.6).
This study confirms that there is an increased incidence of lymphoma in patients with pSS. An increase in the incidence of other cancers was not proven but the observation that some patients developed more than one cancer raises the possibility that there may be a subgroup of patients who are at greater risk of developing cancer.
比较原发性干燥综合征(pSS)患者队列与英格兰同一地区普通人群中后续癌症的发病率。
对1979年起在伦敦大学学院医院门诊就诊的112例患者进行回顾性分析。对患者从pSS诊断至首次后续癌症诊断、死亡、失访或2003年12月31日(截尾日期)进行随访,以确定每个个体的风险人年数。后续癌症的预期数根据英格兰东南部普通人群的性别/年龄/时期特异性发病率计算得出,这些发病率来自泰晤士癌症登记处的登记数据。然后计算标准化发病率(SIR),即观察到的癌症数与预期癌症数之比,以及95%置信区间(CI)。对所有恶性癌症、淋巴瘤和非淋巴瘤癌症进行单独分析。
在112例pSS患者中,25例发生癌症(pSS发病之前或之后),其中11例为淋巴瘤。9例患者患两种癌症。与普通人群相比,pSS患者中淋巴瘤的发病率显著升高(SIR 37.5,95%CI 20.7 - 67.6)。对于非淋巴瘤癌症,观察到的发病率增加较小且无统计学意义(SIR 1.5,95%CI 0.9 - 2.6)。
本研究证实pSS患者中淋巴瘤发病率增加。其他癌症发病率增加未得到证实,但一些患者发生不止一种癌症的观察结果提示可能存在患癌风险更高的亚组患者。